Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Still in omeros?
Doc,
thanks for the heads up,
snup
ceo said Data for 721 igan was going to be released around midyear , if positive easy double , could be released any day now , also preparing to file BLA for stem cell TMA , FDA said it would be the best thing to do to get it to market asap , possible end 2018 , early 2019. At pps 19 the risk dwarves the rewards , also within 10 weeks omidria starts selling again with extended reinbursement and added to VA , SO MUCH GOING ON , ITS CRAZY
When are we getting news on 721? Market starting to feel something is not right with trials?
OMER NEWS "Obtains Approval to Initiate Phase 1 Clinical Trial for its OMS527 Addiction Treatment
https://finance.yahoo.com/news/omeros-obtains-approval-initiate-phase-131500089.html
Omeros!
Wow, just checking the price , thought I would see 7-9 bucks or so
wow, have not been following omer for a while, congrats everyone
been chasing oil for some time now
enjoy!
snupDAWGoled
Still waiting, is Greg going to wait till last minute?
Give it 4 more weeks, euro partner for omidria about to be announced with possible milestone payment to remove risk of dilution, final igan ph2 data, 721 tma BLA filling for AA and start clinical trials for oms527 addiction program,20% short ,almost all shorted under 18 with no volume to cover without moving it up
Had I waited to buy 48 hours later, I would have saved $2500.
Not great timing.
Opti
Don’t worry. It has only Just started. Give it 3 months.
My Bad; I finally bought yesterday near the high. Been watching it go up daily and figured, "surely this is going to continue."
Sorry.
Opti
8-k...
Item 8.01 Other Events.
On March 23, 2018, President Donald J. Trump signed into law the Consolidated Appropriations Act, 2018 (the “Act”). A bipartisan-supported provision in the Act extends pass-through reimbursement status for a small number of drugs used during procedures performed on Medicare Part B fee-for-service patients for an additional two years, effective October 1, 2018 through September 30, 2020. The drugs that qualify for this extension are those for which previously existing pass-through reimbursement status expired on December 31, 2017 and which became included as part of the packaged procedural payment as of January 1, 2018. OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%, the U.S.-marketed drug product of Omeros Corporation, is one of the drugs for which pass-through reimbursement status was extended pursuant to the Act. As a result of this extension, each of these drugs, for the two-year period beginning October 1, 2018, will receive separate payment at a rate of average sales price, or ASP, plus six percent, consistent with almost all other physician-administered drugs that come off pass-through status.
FourWorld Capital Issues Eye-Opening Research Report on Drugmaker Omeros; Concludes Company Faces Perilous Future Following Loss of Medicare Support for Propping up Price of its Sole Commercial Product
Font size: A | A | A
9:00 AM ET 2/14/18 | PR Newswire
RELATED QUOTES
Company's ophthalmic product for pupil dilation, easily replicated with cheaper alternatives, recently lost Medicare pass-through status, making it vastly more expensive than competitive products; Omeros now buying up unused inventory of its drug Omidria
NEW YORK, Feb. 14, 2018 /PRNewswire/ -- FourWorld Capital Management, LLC has published the results of an in-depth analysis of biopharmaceutical company Omeros that cast serious doubt on the financial viability of the company, owing to a perfect storm of deteriorating revenue prospects and an uncertain pipeline of new drugs, along with the loss of a key legislative option propping up the price of its sole product.
FourWorld believes all regulatory and legislative options to extend pass-through Medicare reimbursement status past January 1, 2018 for its only marketed product have been singularly unsuccessful and are now no longer viable. FourWorld forecasts a $400 million funding shortfall and believes the fair value for Omeros common stock is $4/share.
Blinded by reality: costly drug that may be a 'nice to have' but not a 'need to have'
Seattle-based Omeros (Nasdaq: OMER) markets a single patented and FDA-approved medication, called Omidria, a cocktail of legacy generic pupil dilation and pain relief drugs that can be used in cataract surgeries. Medicare's pass-through reimbursement system has allowed Omeros to charge providers up to $465 per dose of Omidria, a gross price mark-up for a product whose ingredients cost, as FourWorld understands, approximately $2.50 per dose and whose two-ingredient alternatives, proven and easily obtainable since at least the 1950s, are priced at about $30 a dose.
FourWorld lays out its concerns for the company in a new report entitled Omeros Corporation: Far Less Than Meets the Eye. It is available at fourworldcapital.com.
In its report, FourWorld notes that Medicare, describing Omidria as a "nice-to-have" but not a "need-to-have" product, ended "pass-through" reimbursement for the drug as of January 1. As a result, FourWorld expects Omeros will be required to reduce the price of Omidria by up to 90% to prevent a mass exodus to less expensive and, as FourWorld reports, equally effective options.
Loss of the Medicare safety net and exposure of its sole commercial product to potentially lethal competition has placed Omeros in a triple bind: even as it plies providers with free samples of Omidria to retain them as customers, channel checks indicate that eye surgeons and wholesalers are cutting back on their procurement of the drug now that the cost charged by Omeros is no longer covered by taxpayers.
Simultaneously, FourWorld explains that Omeros has been repurchasing, at full price, unused Omidria inventory from customers. Additionally, the company's own OmidriaAssure program pays providers the difference between their cost for Omidria and patient insurance.
FourWorld's conclusion: it doesn't take 20/20 vision to recognize that a financial model such as this is unsustainable.
Throughout 2017 Omeros affirmed its optimism that a pass-through extension would be forthcoming. But reality may have caught Omeros investors by surprise. The company has pinned its hopes on two pieces of legislation -- HR 4679 and HR 4683 -- that conceivably provided a path back to Medicare support for Omidria. But the Bipartisan Budget Act of 2018 -- signed into law on February 9 -- included 377 pages on healthcare spending but nothing that extended reimbursement status. FourWorld and its government affairs experts believe that this omission essentially kills all hope for the two bills. FourWorld notes that all of Omeros' assets are pledged as collateral under its $125 million term loan agreement, essentially leaving shareholders at the mercy of the performance of Omidria.
Based on FourWorld's interviews with cataract surgeons, the report says, "Omidria would need to reprice at a 90% discount to start being of interest. We believe these cost cuts represent the bare minimum cut to Omidria's price for OMER to have any chance of defending its current market share."
The report goes on to forecast an 80% year-over-year revenue decline for Omidria, given that "Omeros has exhausted all viable regulatory and legislative options to extend reimbursement status."
New York-based FourWorld Capital is an SEC-registered investment advisor focusing on event-driven investment opportunities. The firm was founded by John Addis, formerly head of Americas Equity Finance at Bank of America Merrill Lynch.
"Omeros markets a single commercial product that has little clinical benefit which surgeons we've consulted are unwilling to pay for," Mr. Addis said. "Loss of Medicare reimbursement has removed the drug's financial lifeline the company's financial underpinning."
He continued, "Investors should have a clear understanding that Omeros is facing massive cash flow burn and resulting credit risk under its term loan agreement. The situation might be arguably brighter if there were viable therapies in the company's pipeline, but our research indicates that the pipeline is highly uncertain, pledged to creditors, and at best years away."
Too clear not to see: Omeros' shaky finances
As outlined by FourWorld's research, Omeros is subject to challenging covenants and possible termination provisions under its $125 million term loan agreement. Owing to the loss of its Medicare support and lack of viable therapies in the company's pipeline beyond this year, the company is unlikely to ever again meet either its minimum revenue or market cap tests, which are required to be met annually under the terms of the loan agreement.
The company's debt capacity presents a formidable dilemma. FourWorld's research shows that Omeros has $45 million in debt capacity expiring on March 21, 2018. If this debt is drawn in full, it puts further pressure on the market cap test -- if fully drawn, the minimum requirement under the loan would be $800 million versus Omeros closing market cap on Feb 9(th) of just above $600 million. If the debt remains undrawn, the capacity will expire and Omeros will almost certainly need to seek liquidity elsewhere, via either a large and dilutive equity offering or additional debt.
According to FourWorld's report, Omeros disclosed to investors that, irrespective of Congress's decision on Medicare pass-through for Omidria, the company has, in its words, "incremental sources of funds" to finance the business only until November 9. FourWorld's report continues: "Given the covenants in the Term Loan, we believe there are few incremental funds at its disposal, and the Company will be facing a budget crisis in the face of collapsing OMIDRIA revenues and rising operating expenses. The logical place to turn will be the capital markets -- which we believe equates to an imminent large equity offering and likely multiple additional equity offerings over the next 12 to 24 months."
"To address the near-term liquidity needs we forecast above," the report concludes, "we estimate that Omeros will need to do a $150 million equity offering in the very near future, with at least $90 million used to repay the [lender's] Loan and the remaining $60 million, together with the remaining cash on hand, to fund its operations for 2018. In subsequent years, we believe Omeros will need to raise an additional $100 million per year to fund its operations until drugs in its pipeline either produce material revenues or reach milestones that have significant collateral value to justify a debt offering (e.g. full FDA approval), which we estimate will not happen until 2022, if at all. In total, we estimate that current investors could be looking at approximately $400 million in capital raising requirements over the next four years."
About FourWorld Capital
FourWorld Capital Management LLC is an SEC-registered investment adviser based in New York. FourWorld focuses on event-driven investment opportunities. For more, visit www.fourworldcapital.com.
Following the publication of this report, FourWorld intends to continue transacting in the securities covered herein. The firm may be long, short, or neutral at any time hereafter regardless of its initial recommendation.
Contact: Allan Ripp 212-262-7477 aripp@rippmedia.com
FourWorld Capital Management, LLC is a member of the Financial Industry Regulatory Authority, CRD number 284138.
View original content:http://www.prnewswire.com/news-releases/fourworld-capital-issues-eye-opening-research-report-on-drugmaker-omeros-concludes-company-faces-perilous-future-following-loss-of-medicare-support-for-propping-up-price-of-its-sole-commercial-product-300598611.html
SOURCE FourWorld Capital Management LLC
/Web site: http://www.fourworldcapital.com
> Dow Jones Newswires
February 14, 2018 09:00 ET (14:00 GMT)
Doc,
thanks for info,
Make it a great Thanks, giving!
snup
I know eglt works on a abuse resistant opioid, but i havent done DD on the company, waiting here for breaktrough therapy designation for GVHD and prime status in europe, and start of a few ph3 trials for oms721 before making a trade here
Too much about to happen here next 5 weeks to sell at these prices
Gltu
Had to leave omer, and adding more
eglt and dnr Oil is good for 18!
doc,
Know you do dd on eglt, for me at a minimum
50% gain coming by end of dec.
short trade view
long view,
hold for multi bagger into 18 yeah, eglt is gonna recover
like a bull run
snupDawg
Doc,
Don't know why your trying to hand me cash but I am grateful,
just got home what a jump for omer my currrent couple of shares
will be green again
I have what is left of cash in dnr and gte I can trade out of
both for either omer or eltp I will listen to eltp in a few
minutes.
Again , I am grateful to you, and will offer up my quiet time
today to your private intentions.
snup
You should read cc transcript when its out
Fda could approve 721 for igan before trial ends, 5 billion market, no approved treathment yet
Sure you heard this before but 2018 gonna be a gamechanger
fda is on their neck to get this product to market asap
Doc,
not yet but I had the itch in the 13's will keep my eye on it
good days ahead for you!
snup
Stellar Quarter and CC
Gonna booooooooom
Hope you're in on the dip
I surely hope this is temporary. i had a good profit but i'm almost back at my starting point.
anyhow, i'm in long, so better leave it as it is till 2018....
XBI biotech index has been down for over 2 weeks, that has put some pressure on OMER, imo, despite the good news.
Going to 17 (Ma200) imo
3 positive updates and price drops from 25 to 17.5
Good time to jump aboard
_They granted 15 years exclusivity on omidria
_Sucsesfull tratment of patient with both stem cell transplant associated thrombotic microangiopathy & graft versus host disease
_New indication for oms721 to pursue
And price drops
Where is the logic ?
Doc,
Smile so true, it is all I have left for omer right now
I moved heavily into GTE Do some dd it may interest you.
oil above 50, cad/dollar a positive,company for me is ready
to run.
snup
Ready to make some dollars today ?
Bought 1900 shares, wish I had more coin below 20
is The Sweet SPOT
snup
Right now I am in gte , innv, with omer monies
but man oh man that sweet spot for me is back,
hopefully , I can get back in if I can move some
other funds.
omer is a long term keeper but McD monies while we wait.
snup
well, chump change profit but had to sell
have been buying gte, I think oil is going
to stay above 50
hopefully will be back to omer soon
as it is a great long term hold.
snup
#TMAboston speaker Dr Andrew Siedlecki @OmerosCorp OMS721 pic.twitter.com/1t9OBMU4y0
— aHUS Alliance Action (@aHUSAllianceAct) August 24, 2017
Doc,
Just clicking for me with Omeros,
but man, I am down huge on elite,
snup
Adam feuerstein released another hit piece on omeros pre market, but market bought the dip , green before lunch,
Omer just finished a capital round to fund them the next 2 year with only 3mil dilution
Much stronger company now, you made a helluva deal buying that dip
Already up 8% or so, lets hope these short soon cover at a loss instead of releasing false news to bring it down
$200,000,000 in open short positions
20% Short
squeeze about to happen
Got another 2600 today below 20 bucks!
Had to keep my profits before taxes from last flip
though.
Blessings to all omer longs
snup
No, welder in school and renovating old building in professional life
Far from high education
LOL
sorry misspelled
A corpsman/doc, or medical military personnel
Whats a corpsemen?
Doc,
Fine witness thank you! Why are 12-step programs such as AA
so successful, It is in the appeal to a Higher power
I wish you well Doc, Were you by any chance a corpesmen?
snup
Been down the same road 20 years ago bud.
Dope with young girl, paying for her, pregnancy, abortion, flat broke, dealing stealing and finaly jail
Once out changed my life completely
Now 20yr later, own 2 houses, 2 beautifull daughters and 3th underway, sweet girl, own renovation business and money in the bank
If i could do my life all over again
I wouldnt change a thing
SERIOUS
Good morning Doc.
needed access for cash/bills thank you for suggesting omer
at around what? 6 or 7 bucks? will get back into it soon enough
the childish prattle on both sides needs to stop
make it a great weekend,
snup
You sold at the right time, -6% yesterday
normaly friday we bounce, hope this korea joke wont destroy markets sentiment for too long
Take care
Had to sell today, needed that 10k profit
just got out of rehab/detox , can you believe
it they took my devises away for a time.
well,
not my first rodeo, went in with a young adult friend
who shares drugs with me, Her mom asked me to go with her.
Nice guy that I am , I even paid her co-pay
well, I will get back into omer again.
good fortune men,
snup
listened to it yesterday, very bullish call and earnings
3 ph3 to start next few months,
quote
once the products are on the market, it will be amazing - the other programs that we're going to be able to run.
Q2 results will be around 15 mil
Dont know if that will please wall street, but we cant change that, untill full reinbursement Q to Q revenue will grow slow
After full reinbursement granted rev will kink up.
But thats just a lifeline for now
OMS721 is why everyone should buy and hold at these prices
and hopefully good Q2 results and off we go.....
Already huge winner if one bought 6 months ago
Euro partner just one of a handfull catalysts coming our way next few months
Financials gonna be stellar too
16mil imho
This is going to be a huge winner. Just wait for the euro partner!
Followers
|
37
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
499
|
Created
|
03/07/11
|
Type
|
Free
|
Moderators |
http://www.omeros.com/
http://finance.yahoo.com/q/ks?s=OMER+Key+Statistics
Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. Our most advanced product candidates are derived from our proprietary PharmacoSurgery® platform designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical and medical procedures. Our PharmacoSurgery platform is based on low-dose combinations of therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery. Omidria™ (phenylephrine and ketorolac injection) 1%/0.3%, the first commercial product from Omeros’ PharmacoSurgery platform, was approved by the FDA in May 2014. Omidria is also currently under review for marketing approval by the European Medicines Agency (EMA). Omeros’ six other clinical programs are focused on schizophrenia, Huntington’s disease, and cognitive impairment; addictive and compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Two additional programs are expected to advance into the clinic next year – one for the control of blood loss during surgery or resulting from trauma and the second for the treatment of a wide range of addictions and compulsions as well as any movement disorder. Omeros also has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development. |
Omeros is developing a deep pipeline of small-molecule and protein therapeutic candidates targeting inflammation, coagulopathies, and disorders of the central nervous system. Our twelve programs include those focused on inflammation, coagulopathies, and multiple CNS disorders, as well as our three platform programs: PharmacoSurgery®, antibody and G protein-coupled receptor all targeting both large-market and exciting orphan opportunities. Products from our proprietary PharmacoSurgery platform, which yielded our first commercial product Omidria™ (phenylephrine and ketorolac injection) 1%/0.3%, for use during cataract surgery and other lens replacement procedures, are designed to improve the clinical outcomes of patients undergoing arthroscopic, urological, and other surgical and medical procedures. Our MASP program is in clinical development to treat thrombotic microangiopathies, including atypical hemolytic uremic syndrome, and a wide range of inflammatory disorders. Our two PDE10 clinical programs for the treatment of schizophrenia and Huntington's disease, our clinical program for the treatment and prevention of addictions and compulsions and our preclinical programs targeting other CNS disorders and coagulopathies further strengthen our pipeline and help create multiple opportunities for commercial success. Our GPCR platform is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development, and our antibody platform enables the discovery of novel, high-affinity monoclonal antibodies. For each of our product candidates and programs, we have retained all manufacturing, marketing and distribution rights. | ||
|
|
Our proprietary PharmacoSurgery® products are designed to improve the clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical and medical procedures. Omidria™ (phenylephrine and ketorolac injection) 1%/0.3%, is the first approved drug from our PharmacoSurgery platform |
We have multiple programs focused on central nervous system (CNS) disorders, all targeting large markets. Our most advanced CNS programs include our phosphodiesterase 10 (PDE10) program, focused on developing drugs for the treatment of schizophrenia, Huntington's disease and other cognitive disorders; our PPARγ program, focused on developing proprietary compositions that include peroxisome proliferator-activated receptor gamma (PPARγ) agonists for the treatment and prevention of addiction to substances of abuse (e.g., opioids, nicotine and alcohol); and our PDE7 program for the development of drugs for the treatment of movement disorders, such as Parkinson's d |
We are developing antifibrinolytic agents for the control of blood loss during surgery or resulting from trauma. Excessive bleeding during cardiac surgery is known to increase overall morbidity and mortality. In an attempt to control this bleeding, patients undergoing cardiac and other extensive surgery often receive antifibrinolytic compounds. These drugs inhibit plasmin, an enzyme present in blood that degrades fibrin clots. Because plasmin degrades fibrin clots, an agent that inhibits plasmin may have potential utility for reducing blood loss due to trauma or surgery. Prior to withdrawal from the market in 2008 for safety concerns, the antifibrinolytic Trasylol® (aprotinin) had been shown in a number of studies to be more effective at reducing blood loss than the other two most commonly used antifibrinolytics on the market today, tranexamic acid and epsilon aminocaproic acid. While Trasylol® is a potent inhibitor of plasmin, it is non-selective. In addition to plasmin, it significantly inhibits kallikrein and Factor XIa, two enzymes important in promoting clotting, and their inhibition can increase bleeding. Trasylol® was found to be associated with a number of safety issues, including increased mortality. Further, it is a bovine protein associated with anaphylactic reactions. While the specific cause of increased death remains unknown, an often-cited explanation is the lack of specificity of Trasylol®. Our proprietary agents also inhibit plasmin but, unlike Trasylol®, they do not significantly inhibit kallikrein and Factor XIa. Additionally, our agents are derived from human protein, which may reduce immunological side effects. The properties of our proprietary agents are described in a peer-reviewed article titled "Engineering Kunitz Domain 1 (KD1) of Human Tissue Factor Pathway Inhibitor-2 to Selectively Inhibit Fibrinolysis: Properties of KD1-L17R Variant" that was published in the February 11, 2011 issue of the Journal of Biological Chemistry. We believe the efficacy and improved selectivity of our proprietary agents provide a novel approach to the control of bleeding from surgery and trauma. We have selected a lead clinical candidate and are manufacturing pre-clinical supplies to enable the initiation of GLP toxicology studies intended to support the submission of an IND or clinical trial application and subsequent clinical trials. We plan to be in clinical trials with our anti-plasmin molecule in 2015. Patent Position As of February 15, 2014, we owned one issued patent and three pending patent applications in the U.S. and seven issued patents and 26 pending patent applications in foreign markets directed to our recent discoveries linking PPAR? and |
G protein-coupled receptors (GPCRs), which mediate key physiological processes in the body, are one of the most valuable families of drug targets. According to Insight Pharma Reports, GPCR-targeting drugs represent 30 to 40 percent of marketed pharmaceuticals. Examples include Claritin® (allergy), Zantac® (ulcers and reflux), OxyContin® (pain), Lopressor® (high blood pressure), Imitrex® (migraine headache), Reglan® (nausea) and Abilify® (schizophrenia, bipolar disease and depression) as well as all other antihistamines, opioids, alpha and beta blockers, serotonergics and dopaminergics. The industry focuses its GPCR drug discovery efforts mostly on non-sensory GPCRs. Of the 363 total non-sensory GPCRs, approximately 240 have known ligands (molecules that bind the receptors) with nearly half of those targeted either by marketed drugs (46 GPCRs) or by drugs in development (about 70 GPCRs). There are approximately 120 GPCRs with no known ligands, which are termed "orphan GPCRs." Without a known ligand, drug development for a given receptor is extremely difficult. Omeros uses its proprietary high-throughput cellular redistribution assay (CRA) to identify small-molecule agonists and antagonists for orphan GPCRs, unlocking them to drug development. Omeros believes that it is the first to possess the capability to unlock orphan GPCRs in high-throughput, and that currently there is no other comparable technology. Unlocking these receptors could lead to the development of drugs that act at these new targets. There is a broad range of indications linked to orphan GPCRs including cardiovascular disease, asthma, diabetes, pain, obesity, Alzheimer's disease, Parkinson's disease, multiple sclerosis, schizophrenia, learning and cognitive disorders, autism, osteoporosis, osteoarthritis and several forms of cancer. Omeros has begun screening orphan GPCRs against its small-molecule chemical libraries using its proprietary, high-throughput CRA. In addition to Class A orphan GPCRs, we have also begun screening orphan and non-orphan Class B receptors. Class B GPCRs have large extracellular domains and their natural ligands are generally large peptides, making the development of orally active, small-molecule drugs against these receptors, such as glucagon and parathyroid hormone, a persistent challenge. Omeros has announced that it has identified and confirmed sets of compounds that interact selectively with the following orphan receptors: | The GPCR family represents an important source of drug discovery. Of the 363 characterized GPCRs, only about 46 are currently targeted by marketed drugs, yet GPCR-targeted drugs account for 30-40% of all drugs sold worldwide. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In parallel, Omeros is executing on its intellectual property strategy to protect each unlocked target through a multipronged approach directed to compound structures, uniquely identified signaling pathways and associated therapeutic indications. Collectively, this approach provides Omeros the opportunity to establish broad and enforceable protection for each unlocked receptor. GPR17We are optimizing compounds against GPR17, a G protein-coupled receptor (GPCR) which is linked to myelin formation. Myelin is an insulating layer rich in lipids and proteins that forms a sheath around the nerve fibers, which is essential for the proper functioning of the nervous system. Loss of the myelin sheath is the hallmark of several diseases, including multiple sclerosis, acute disseminated encephalomyelitis, Neuromyelitis Optica, transverse myelitis, chronic inflammatory demyelinating polyneuropathy, Guillain-Barré syndrome, central pontine myelinosis, inherited demyelinating diseases such as leukodystrophy, and Charcot-Marie-Tooth disease. We believe GPR17 inhibitors have the potential to promote remyelination and improve the outcome of these diseases as well as traumatic brain injury and spinal cord injury, conditions that have been associated with GPR17. Discovering GPR17 inhibitors has previously been challenging to the pharmaceutical industry because this receptor is an orphan GPCR. However, using our proprietary CRA, we have been able to identify over 100 compounds that functionally interact with GPR17. We are now in the process of developing lead molecules targeting GPR17, which we intend to evaluate in remyelination assays in cell culture systems as well as in animal models. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Patent Position As of February 15, 2014, we owned five issued patents and 10 pending patent applications in the U.S., and 43 issued patents and eight pending patent applications in foreign markets , which are directed to previously unknown links between specific molecular targets in the brain and a series of CNS disorders, our cellular redistribution assay and other research tools that are used in our GPCR program and to orphan GPCRs and other GPCRs for which we have identified functionally interacting compounds using our cellular redistribution as |
Our proprietary ex vivo platform for the discovery of novel, high-affinity monoclonal antibodies utilizes a chicken B-cell lymphoma cell line and has demonstrated potential for the generation of diverse antibodies that can be readily engineered. This platform offers several advantages over other antibody platforms. The ex vivo immunizations of our proprietary cell line are significantly more rapid than whole animal immunizations and conventional hybridoma technology. By avoiding immunization of mice or other animals, we believe that the antibodies we generate from this platform are not limited by immunological tolerance. Our platform is capable of producing novel antibodies against difficult targets, such as highly homologous proteins, enzymes, and receptors with short extracellular domains. Chicken antibodies also have unique features that enable binding capabilities distinct from mammalian antibodies. We have generated antibodies to several clinically significant targets, and our platform continues to add antibodies against additional important targets to our pipeline. Patent Position As of February 15, 2014, we owned and/or held worldwide exclusive license rights from the University of Washington to three pending U.S. Patent Applications, four foreign patent applications and one International Patent Cooperation Treaty Patent Application directed to our antibody platform. Additionally, we owned one issued U.S. Patent, two pending U.S. Patent Applications and eight pending foreign applications directed to antibodies generated |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |